EMBL researchers are studying how drugs that have shown good results against COVID-19 work in living cells
To identify drugs that are effective against COVID-19, we need to understand how they work, known as their mode of action (MoA). EMBL researchers are using a technology called thermal proteome profiling, which can systematically identify targets for potential drugs in living cells. This will be used to identify which proteins in the cell are targeted by approved drugs that have shown potential against COVID-19. Most of these drugs are used against other diseases, but their MoA is still unknown. Identifying their MoA will help scientists to quickly propose other efficient drugs or drug combinations to treat COVID-19, which are urgently needed until a vaccine is developed and made available globally. Drugs will possibly be needed afterwards too, if COVID-19 becomes seasonal, as backup therapies when vaccination fails to cover individual people.
The project will rely on services provided by EMBL’s Proteomics Core Facility (PCF). The PCF helps scientists from EMBL and other institutions to identify proteins and study their physical and chemical properties. The facility provides state-of-the-art mass spectrometry. This is an essential tool for the analysis of proteins, and is needed to understand the MoA of potential drugs against COVID-19.
It’s almost a year since the coronavirus outbreak was declared a pandemic, affecting all our lives. While the virus continues its grip on the world, scientists are understanding it better and better, increasing our knowledge about it and opening up new ways to fight it.